F.S.S.A., H.A.H.A., I.T., N.S.S.A., and R.H. Fc modification to increase its half\life in the respiratory mucosa. 7 The interaction with Fc receptors can also mediate clearance of virus\infected cells through a variety of immune effector mechanisms. 5 , 6 On the other hand, favipiravir is an anti\influenza drug that early in the pandemic was reported to have inhibitory activity against SARS\CoV\2 and it has been used as an antiviral agent to treat COVID\19. 8 It is a nucleotide analogue prodrug that selectively inhibit viral RNA polymerase complex and result in SARS\COV\2 lethal mutagenesis. 8 However, the efficacy of favipiravir therapy is still debatable in non\hospitalized patients with mild to moderate COVID\19 9 , 10 , 11 but was commonly used in multiple countries’ COVID\19 treatment\protocols until recently. Sotrovimab efficacy among high\risk patients with mild to moderate COVID\19 was based on recent published clinical trials that found a single intravenous Temsirolimus (Torisel) dose of sotrovimab (500?mg), compared with placebo, significantly reduced the risk of all\cause hospitalization or death through day 29. 1 , 12 Furthermore, sotrovimab was also associated with a reduction from baseline to day 8 in nasopharyngeal viral load and reduction from baseline to day 7 in the FLU\PRO Plus questionnaire total score of COVID\19 related symptom severity and duration. 12 Therefore, the lower number of these events prompted a conditional recommendation of its use by treatment guidelines Temsirolimus (Torisel) panels. 13 Moreover, there are, to our knowledge, no published real\world data on the effectiveness of sotrovimab treatment to prevent development of severe COVID\19 and its outcomes. We therefore sought to examine the association between sotrovimab treatment and the risk of hospitalization or death among a large population\based cohort of patients with COVID\19 in the city of Dubai, United Arab Emirates. METHODS Study design This study was a retrospective analysis of administrative data from the SALAMA healthcare system. SALAMA is the Dubai Health Authoritys (DHA) unified electronic medical record system which covers all the hospitals and clinics under the Government of Dubai. The study used patients data of those who received sotrovimab infusion (a single dose of 500?mg), a combination of sotrovimab infusion and oral favipiravir (1,600?mg twice a day on day 1 and then 600? mg twice a day for 10?days), or oral favipiravir alone at any Dubai COVID\19 related healthcare center between June 22, 2021, and October 31, 2021. The retrieved data from the SALAMA system for each of the patient were as follows; patients demographics, such as age, gender, and nationality; date of COVID\19s positive reverse transcriptaseCpolymerase chain reaction (RT\PCR) and negative RT\PCR test results, type and date of medication received being either sotrovimab and/or Temsirolimus (Torisel) favipiravir; date for other COVID\19 adjacent therapy, such Temsirolimus (Torisel) as ascorbic acid and cholecalciferol; COVID\19 related\symptoms and oxygen saturation level SpO2 at the time of receiving treatment; post\infusion status of sotrovimab; type and date of different doses of COVID\19 vaccine received being mRNA vaccine; diagnosis name, problem lists, and medical history at patient level; next visit date, location (name of clinic or hospital), and department name (family medicine clinic or emergency department); and survival status (alive/dead). Patients and treatment selection The studied patients were aged 18?years or older, tested positive for SARS\CoV\2 by RT\PCR test, and had mild Temsirolimus (Torisel) to moderate COVID\19 related symptoms with SpO2??94% on room air that did not require hospital admission. Mild illness was defined as individuals with any of the following signs and symptoms of COVID\19 (e.g., fever, cough, sore throat, malaise, headache, and muscle pain) without shortness of breath, dyspnea, or abnormal chest Eno2 imaging. Whereas moderate illness was defined as individuals who have evidence of lower respiratory disease by.